Gainers

• NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.8 million.
• Shuttle Pharmaceuticals (NASDAQ:SHPH) stock moved upwards by 72.93% to $5.12. The market value of their outstanding shares is at $1.7 million.
• Picard Medical (AMEX:PMI) shares increased by 23.43% to $0.18. The company's market cap stands at $14.6 million.
• Ensysce Biosciences (NASDAQ:ENSC) stock rose 16.15% to $0.32. The company's market cap stands at $4.2 million.
• Bluejay Diagnostics (NASDAQ:BJDX) shares rose 14.75% to $1.4. The market value of their outstanding shares is at $1.2 million.
• Polyrizon (NASDAQ:PLRZ) stock rose 14.35% to $15.85. The company's market cap stands at $28.8 million.

Losers

• Matinas BioPharma Hldgs (AMEX:MTNB) shares decreased by 19.8% to $0.38 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.0 million.
• Evotec (NASDAQ:EVO) stock fell 13.59% to $2.1. The company's market cap stands at $863.8 million.
• XTL Biopharmaceuticals (NASDAQ:XTLB) shares decreased by 12.16% to $2.53. The market value of their outstanding shares is at $7.0 million.
• Trevi Therapeutics (NASDAQ:TRVI) shares fell 12.11% to $14.52. The market value of their outstanding shares is at $2.3 billion.
• China Pharma Holding (AMEX:CPHI) stock declined by 11.61% to $0.55. The company's market cap stands at $25.3 million.
• CNS Pharmaceuticals (NASDAQ:CNSP) shares declined by 11.6% to $4.5. The market value of their outstanding shares is at $7.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.